Skip to search formSkip to main contentSkip to account menu

168 HR Buprenorphine 0.0075 MG/HR Transdermal System [BuTrans]

Known as: BuTrans 7.5 MCG/HR 7 Day Transdermal Patch, Butrans 7.5 MCG/HR 7 Day Transdermal System, 168 HR BuTrans 0.0075 MG/HR Transdermal System 
National Institutes of Health

Related topics

Related topics

6 relations
BuTransBuprenorphinePovidoneTransdermal System

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2014
Review
2014
Use of the low-dose buprenorphine patch: a response.
Dear Editor: As the NDA holder and distributor of Butrans® (buprenorphine) Transdermal System, Purdue Pharma L.P. works to… 
Review
2013
Review
2013
Buprenorphine transdermal system and quality of life in opioid-experienced patients with chronic low back pain
Objectives: To evaluate the impact of 12 weeks of treatment with Butrans® (buprenorphine) transdermal system (BTDS) on the health… 
2012
2012
PSY6 The Impact on Sleep Quality of Butrans® (Buprenorphine) Transdermal System 5 Mcg/Hour (BTDS 5) and 20 Mcg/Hour (BTDS 20) Dosages in Patients With Moderate-to-Severe Chronic Low Back Pain
2011
2011
A Randomized, Double-Blind, Double-Dummy Comparison of the Efficacy and Tolerability of Low-Dose Transdermal Buprenorphine (BuTrans® Seven-Day Patches) With Buprenorphine Sublingual Tablets (Temgesic…
2011
2011
Time dependency of adverse events with Butrans™ (buprenorphine) transdermal system
2011
2011
Butrans™ (buprenorphine) Transdermal System Improves the Quality of Sleep in Patients with Moderate-To-Severe Chronic Pain
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)